Executive Director, CLSI CARB-X
Heather Shane leads the CARB-X accelerator at CLSI, providing non-dilutive funding, entrepreneurial support and subject matter expertise to start-ups with innovative antibiotic product candidates. CARB-X, an international consortium comprised of leaders in industry, philanthropy, government and academia, is the world’s largest public-private partnership focused on combating antimicrobial resistance. Prior to joining CLSI, Heather served as Vice President & Assistant General Counsel at Theravance Biopharma (TBPH), a Bay Area biopharmaceutical company, and Theravance (now known as Innoviva), where she handled a broad range of corporate, financing, partnering, operational and regulatory compliance matters, and experienced antibiotic drug discovery transitioning to and through preclinical and clinical development, the regulatory process and ultimately commercialization. Before joining Theravance, Heather was a corporate attorney with Gunderson Dettmer Stough Villeneuve & Hachigian where she represented start-ups, venture capital and public company clients in a variety of transactions.